A cost-effectiveness evaluation of imatinib versus interferon-alpha plus low-dose Ara-C for first-line treatment of patients with newly diagnosed chronic myeloid leukemia in the chronic phase.
Publication
, Conference
Reed, SD; Anstrom, KJ; Foster, JA; Glendening, AG; Schulman, KA
Published in: BLOOD
November 16, 2003
Duke Scholars
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2003
Volume
102
Issue
11
Start / End Page
252A / 252A
Location
SAN DIEGO, CALIFORNIA
Publisher
AMER SOC HEMATOLOGY
Conference Name
45th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Reed, S. D., Anstrom, K. J., Foster, J. A., Glendening, A. G., & Schulman, K. A. (2003). A cost-effectiveness evaluation of imatinib versus interferon-alpha plus low-dose Ara-C for first-line treatment of patients with newly diagnosed chronic myeloid leukemia in the chronic phase. In BLOOD (Vol. 102, pp. 252A-252A). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY.
Reed, S. D., K. J. Anstrom, J. A. Foster, A. G. Glendening, and K. A. Schulman. “A cost-effectiveness evaluation of imatinib versus interferon-alpha plus low-dose Ara-C for first-line treatment of patients with newly diagnosed chronic myeloid leukemia in the chronic phase.” In BLOOD, 102:252A-252A. AMER SOC HEMATOLOGY, 2003.
Reed SD, Anstrom KJ, Foster JA, Glendening AG, Schulman KA. A cost-effectiveness evaluation of imatinib versus interferon-alpha plus low-dose Ara-C for first-line treatment of patients with newly diagnosed chronic myeloid leukemia in the chronic phase. In: BLOOD. AMER SOC HEMATOLOGY; 2003. p. 252A-252A.
Reed, S. D., et al. “A cost-effectiveness evaluation of imatinib versus interferon-alpha plus low-dose Ara-C for first-line treatment of patients with newly diagnosed chronic myeloid leukemia in the chronic phase.” BLOOD, vol. 102, no. 11, AMER SOC HEMATOLOGY, 2003, pp. 252A-252A.
Reed SD, Anstrom KJ, Foster JA, Glendening AG, Schulman KA. A cost-effectiveness evaluation of imatinib versus interferon-alpha plus low-dose Ara-C for first-line treatment of patients with newly diagnosed chronic myeloid leukemia in the chronic phase. BLOOD. AMER SOC HEMATOLOGY; 2003. p. 252A-252A.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2003
Volume
102
Issue
11
Start / End Page
252A / 252A
Location
SAN DIEGO, CALIFORNIA
Publisher
AMER SOC HEMATOLOGY
Conference Name
45th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology